Type 2 diabetes
The link to this joint publication is now live on the Diabetologia/Springer website
https://link.springer.com/article/10.1007/s00125-026-06855-7
Free open source pdf
Vol.:(0123456789)Diabetologia
https://doi.org/10.1007/s00125-026-06855-7
CONSENSUS REPORT
Management of type 2 diabetes, 2026. A consensus report
by the American Diabetes Association (ADA) and the European
Association for the Study of Diabetes (EASD
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the
consensus statement on the management of type 2 diabetes in non-pregnant adults, published since 2006 and last updated in
2022.
The target audience is the multidisciplinary healthcare team providing diabetes care in the USA and Europe. A system-
atic examination of publications since 2022 informed new recommendations.
This update has broadened the focus from the
management of hyperglycaemia
• to the holistic management of type 2 diabetes and its risk of associated multiple long-term
conditions.
1. Fundamental aspects of diabetes care include
• promoting healthy lifestyle behaviours (healthy eating, 24 h physical
• behaviours including sleep, and
• avoiding tobacco and substance use),
• alongside the provision of psychological support and weight management interventions.
2. For the management of people living with type 2 diabetes, earlier use, potentially from
diagnosis, of sodium–glucose cotransporter 2 (SGLT2) inhibitors or/and glucagon-like peptide-1 (GLP-1)-based therapies
to offer organ protection and improve long-term outcomes in type 2 diabetes is advocated.
3. Furthermore, earlier combination
use of SGLT2 inhibitors and GLP-1-based therapies should be considered in people with concomitant CVD, chronic kidney
disease and heart failure.
4. Finally, the ability to transform outcomes for people living with type 2 diabetes is within our grasp
through the consistent, equitable and systematic implementation of strategies and therapies that are already available.
Nyhetsinfo
Läs hela dokumentet open source free pdf
www red DiabetologNytt